Available COVID-19 vaccine platforms: A roadmap to eclipsing the SARS-CoV-2 viral saga
DOI:
https://doi.org/10.3823/853Keywords:
COVID-19, Novel Vaccine, Platforms, Antibodies, SARS-CoV-2 ImmunityAbstract
The coronavirus disease 2019 (COVID-19) have devastated the globe and continues to be a protracted saga. In the absence of specific efficacious medical remedies, efforts to encounter and contain this emerging virus concentrated on vaccine production. A plethora of novel vaccines has been under development by major companies in different countries. To date, around 60 vaccines are in clinical trials with many other ones continuously added to the evolving pipeline. The variety in their corresponding designed platform and phases, warrants to tackle and understand what is being presented in the literature and launched in the market.
Thus, this study is intended to enlighten and educate the medical community by reviewing the different vaccine platforms, and briefly explaining their mechanism of action with an emphasis on those that reached most advanced stages.
References
Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, Yuen KY.
Genomic characterization of the 2019 novel human-pathogenic
coronavirus isolated from a patient with atypical pneumonia
after visiting Wuhan. Emerg Microbes Infect. 2020; 9(1):221-
doi: 10.1080/22221751.2020.1719902. Erratum in: Emerg
Microbes Infect 2020; 9(1):540. PMID: 31987001.
Scerri M, Grech V. To wear or not to wear? Adherence to
face mask use during the COVID-19 and Spanish influenza
pandemics. Early Hum Dev 2020:105253. doi: 10.1016/j.
earlhumdev.2020.105253. Epub ahead of print. PMID:
Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z.
Immunological considerations for COVID-19 vaccine strategies.
Nat Rev Immunol 2020; 20(10):615-632. doi: 10.1038/s41577-
-00434-6. Epub 2020 Sep 4. PMID: 32887954.
Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR,
Subbarao K, Collins PL. Contributions of the structural proteins
of severe acute respiratory syndrome coronavirus to protective
immunity. Proc Natl AcadSci U S A 2004; 101(26):9804-9.
doi: 10.1073/pnas.0403492101. Epub 2004 Jun 21. PMID:
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X,
Wang Q, Zhang L, Wang X. Structure of the SARS-CoV-2 spike
receptor-binding domain bound to the ACE2 receptor. Nature
; 581(7807):215-220. doi: 10.1038/s41586-020-2180-5.
Epub 2020 Mar 30. PMID: 32225176.
McAndrews KM, Dowlatshahi DP, Dai J, Becker LM, Hensel J,
Snowden LM, Leveille JM, Brunner MR, Holden KW, Hopkins
NS, Harris AM, Kumpati J, Whitt MA, Lee JJ, Ostrosky-Zeichner
LL, Papanna R, LeBleu VS, Allison JP, Kalluri R. Heterogeneous
antibodies against SARS-CoV-2 spike receptor binding domain
and nucleocapsid with implications for COVID-19 immunity. JCI
Insight. 2020; 5(18):e142386. doi: 10.1172/jci.insight.142386.
PMID: 32796155.
Remy KE, Mazer M, Striker DA, Ellebedy AH, Walton AH,
Unsinger J, Blood TM, Mudd PA, Yi DJ, Mannion DA, Osborne
DF, Martin RS, Anand NJ, Bosanquet JP, Blood J, Drewry
AM, Caldwell CC, Turnbull IR, Brakenridge SC, Moldwawer
LL, Hotchkiss RS. Severe immunosuppression and not a
cytokine storm characterizes COVID-19 infections. JCI Insight.
; 5(17):e140329. doi: 10.1172/jci.insight.140329. PMID:
Araj GF, Beaini M, Bizri NA, & Ghizzawi L. Testing for COVID-19:
When, who, and what test? J Med Liban 2020; 68 (1-2): 16-26.
Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y,
Pizzato HA, Thompson MR, Bradshaw C, Weinkauf CC, Bime
C, Erickson HL, Knox K, Bixby B, Parthasarathy S, Chaudhary
S, Natt B, Cristan E, El Aini T, Rischard F, Campion J, Chopra
M, Insel M, Sam A, Knepler JL, Capaldi AP, Spier CM, Dake
MD, Edwards T, Kaplan ME, Scott SJ, Hypes C, Mosier J, Harris
DT, LaFleur BJ, Sprissler R, Nikolich-Žugich J, Bhattacharya D.
Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance
of Low-Prevalence Communities and Reveal Durable Humoral
Immunity. Immunity 2020; 53(5):925-933.e4. doi: 10.1016/j.
immuni.2020.10.004. Epub 2020 Oct 14. PMID: 33129373.
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H,
Wang Y, Zhou Y. Prevalence of comorbidities and its effects
in patients infected with SARS-CoV-2: a systematic review and
meta-analysis. Int J Infect Dis 2020; 94:91-95. doi: 10.1016/j.
ijid.2020.03.017. Epub 2020 Mar 12. PMID: 32173574.
Dan J, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni
A, Ramirez SI, Haupt S, Frazier A, Nakao C, Rayaprolu V,
Rawlings SA, Peters B, Krammer F, Simon V, Saphire EO, Smith
DM, Weiskopf D, Sette A, Crotty S. Immunological memory
to SARS-CoV-2 assessed for up to 8 months after infection.
Science 2021:eabf4063. doi: 10.1126/science.abf4063. Epub
ahead of print. PMID: 33408181
Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland
D, Møller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT,
Schwartz RE, Lim JK, Albrecht RA, tenOever BR. Imbalanced
Host Response to SARS-CoV-2 Drives Development of
COVID-19. Cell 2020; 181(5):1036-1045.e9. doi: 10.1016/j.
cell.2020.04.026. Epub 2020 May 15. PMID: 32416070.
Arunachalam PS, Charles TP, Joag V, Bollimpelli VS, Scott
MKD, Wimmers F, Burton SL, Labranche CC, Petitdemange C,
Gangadhara S, Styles TM, Quarnstrom CF, Walter KA, Ketas
TJ, Legere T, Jagadeesh Reddy PB, Kasturi SP, Tsai A, Yeung BZ,
Gupta S, Tomai M, Vasilakos J, Shaw GM, Kang CY, Moore JP,
Subramaniam S, Khatri P, Montefiori D, Kozlowski PA, Derdeyn
CA, Hunter E, Masopust D, Amara RR, Pulendran B. T cellinducing
vaccine durably prevents mucosal SHIV infection
even with lower neutralizing antibody titers. Nat Med 2020;
(6):932-940. doi: 10.1038/s41591-020-0858-8. Epub 2020
May 11. PMID: 32393800.
Lurie N, Saville M, Hatchett R, Halton J. Developing COVID-19
Vaccines at Pandemic Speed. N Engl J Med 2020; 382(21):1969-
doi: 10.1056/NEJMp2005630. Epub 2020 Mar 30. PMID:
WHO track link: https://www.who.int/publications/m/item/
draft-landscape-of-COVID-19-candidate-vaccines. Accessed on
December 25 , 2020.
Humphreys IR, Sebastian S. Novel viral vectors in infectious
diseases. Immunology 2018; 153(1):1-9. doi: 10.1111/imm.12829.
Epub 2017 Sep 26. PMID: 28869761.
Xiang Z, Li Y, Cun A, Yang W, Ellenberg S, Switzer WM, Kalish
ML, Ertl HC. Chimpanzee adenovirus antibodies in humans,
sub-Saharan Africa. Emerg Infect Dis 2006; (10):1596-9. doi:
3201/eid1210.060078. PMID: 17176582.
Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive
status report. Virus Res 2020; 288:198114. doi: 10.1016/j.
virusres.2020.198114. Epub 2020 Aug 13. PMID: 32800805.
Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA Vaccines
for Infectious Diseases. Front Immunol 2019; 10:594. doi:
3389/fimmu.2019.00594. PMID: 30972078.
Jackson LA, Roberts PC, Graham BS. A SARS-CoV-2 mRNA
Vaccine - Preliminary Report. Reply. N Engl J Med 2020;
(12):1191-1192. doi: 10.1056/NEJMc2026616. Epub 2020
Aug 19. PMID: 32813942.
Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine:
past and present experience. Vaccine 1996; (8):735-46. doi:
1016/0264-410x(95)00211-i. PMID: 8817819.
Donaldson B, Lateef Z, Walker GF, Young SL, Ward VK. Viruslike
particle vaccines: immunology and formulation for clinical
translation. Expert Rev Vaccines 2018; 7(9):833-849. doi:
1080/14760584.2018.1516552. Epub 2018 Sep 19. PMID:
Lu X, Chen Y, Bai B, Hu H, Tao L, Yang J, Chen J, Chen Z, Hu
Z, Wang H. Immune responses against severe acute respiratory
syndrome coronavirus induced by virus-like particles in mice.
Immunology 2007; 122(4):496-502. doi: 10.1111/j.1365-
2007.02676.x. Epub 2007 Aug 3. PMID: 17680799.
Plotkin S. History of vaccination. Proc Natl Acad Sci U S A 2014;
(34):12283-7. doi: 10.1073/pnas.1400472111. Epub 2014
Aug 18. PMID: 25136134.
Jimenez-Guardeño JM, Regla-Nava JA, Nieto-Torres JL, DeDiego
ML, Castaño-Rodriguez C, Fernandez-Delgado R, Perlman S,
Enjuanes L. Identification of the Mechanisms Causing Reversion
to Virulence in an Attenuated SARS-CoV for the Design of a
Genetically Stable Vaccine. PLoS Pathog 2015; 11(10):e1005215.
doi: 10.1371/journal.ppat.1005215. PMID: 26513244.
Downloads
Published
Issue
Section
License
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
Articles are published Under License of Creative Commons Attribution 3.0 License ©
Copyright policies & self-archiving
This is our Copyright Policy. We are a RoMEO green journal.
| Author's Pre-print: |  author can archive pre-print (ie pre-refereeing) |
| Author's Post-print: | author can archive post-print (ie final draft post-refereeing) |
| Publisher's Version/PDF: | author can archive publisher's version/PDF |
